@Article{Komorowski2007,
journal="Klinika Oczna / Acta Ophthalmologica Polonica",
issn="0023-2157",
volume="109",
number="4",
year="2007",
title="Zastosowanie przeciwciał anti-TNFα (infliximab) w leczeniu chorej 
z oftalmopatią tarczycową",
abstract="TNFα (tumor necrosis factor alpha) plays a central role in the development of thyroid associated ophthalmopathy (TAO). We describe and document by ophthalmic (CAS and NO SPECS scales) and radiological (MRI) evaluation a positive effect of anti-TNFα antibody (infliximab) administration on active TAO in a 58 years old woman with Graves’ disease. The single dose of infliximab administration resulted in a dramatic reduction of inflammation studies and improvement of visual function as measured by MRI and CAS and NO SPECS scales, without noticeable short-term side effects. A randomized prospective study is needed to determine whether infliximab proves to be sufficiently effective in reducing the inflammatory symptoms of TAO, and whether it can be administered safely for a prolonged period without side effects.",
author="Komorowski, Jan
and Jankiewicz-Wika, Joanna
and Siejka, Agnieszka
and Ławnicka, Hanna
and Kłysik, Anna
and Goś, Roman
and Majos, Agata
and Stefańczyk, Ludomir
and Stępień, Henryk",
pages="457--460",
url="https://www.termedia.pl/Zastosowanie-przeciwcial-anti-TNF-infliximab-w-leczeniu-chorej-r-nz-oftalmopatia-tarczycowa,124,49773,1,1.html"
}